Converting Intravenous Dosing to Subcutaneous Dosing With Recombinant Human Hyaluronidase - Pharmaceutical Technology

Latest Issue
PharmTech

Latest Issue
PharmTech Europe

Converting Intravenous Dosing to Subcutaneous Dosing With Recombinant Human Hyaluronidase
The preferred route of administration for an injected therapeutic agent is subcutaneous (SC), but SC injections are generally limited to no more than 1-2 mL in volume, representing a major challenge, especially for large protein biologics.


Pharmaceutical Technology


18. F. Duran Reynals, "Exaltation de l'Activité du Virus Vaccinal Par les Extraits de Certains Organes," Comptes Rendus Hebdomadaires de Séances et Mémoires de la Société de Biologie. 99, 6–7 (1928).

19. A. Claude and F. Duran-Reynals, "Chemical Properties of the Non-purified Spreading Factor from Testicle," J Exp Med. 65 (5), 661–670 (1937).

20. F. Duran-Reynals, "A Spreading Factor in Certain Snake Venoms and its Relation to their Mode of Action," J. Exp. Med. 69 (1), 69–81 (1939).

21. K. Meyer, "Hyaluronidases," in: The Enzymes, P.D. Boyer Ed., (Academic Press, New York, NY, 3rd edition, 1971), pp. 307–320.

22. K. Meyer, P. Hoffman, and A. Linker, "Hyaluronidases," in The Enzymes, P.D. Boyer, H. Lardy, and K. Myrback, Eds. (Academic Press, New York, NY, 2nd ed., 1960), pp.447–460.

23. R.G. Williams, "The Effects of Continuous Local Injection of Hyaluronidase on Skin and Subcutaneous Tissue in Rats," Anat. Rec. 122 (3), 349–361 (1955).

24. K. Pillwein et al., "Hyaluronidase Additional to Standard Chemotherapy Improves Outcome for Children with Malignant Brain Tumors," Cancer Lett. 131 (1), 101–108 (1998).

25. A.H. Eberhart, C.R. Weiler, and J.C. Erie, "Angioedema Related to the Use of Hyaluronidase in Cataract Surgery," Am. J. Ophthalmol. 138 (1), 142–143 (2004).

26. R.A. Harrison and S.J. Gaunt, "Multiple Forms of Ram and Bull Sperm Hyaluronidase Revealed by Using Monoclonal Antibodies," J. Reprod. Fertil. 82 (2), 777–785 (1988).

27. R.A. Harrison, "Hyaluronidase in Ram serum. Quantitative Determination and Isolation of Multiple Forms," Biochem J. 252 (3), 865–874 (1988).

28. H.Tint and R. Bogash (American Home Products), "Hyaluronidase," US Patent 2676139, Sept. 1, 1950.

29. H.E. Alburn et al. (American Home Products), "Stabilized Hyaluronidase Solution Containing Calcium Chloride, US Patent 2795529, June 11, 1957.

30. C.L. Borders and M.A. Raftery, "Purification and Partial Characterization of Testicular Hyaluronidase," J. Biol. Chem. 243 (13), 3756–3762 (1968).

31. W.F. Lathrop et al., "cDNA Cloning Reveals the Molecular Structure of a Sperm Surface Protein, PH-20, Involved in Sperm-egg Adhesion and the Wide Distribution of its Gene among Mammals,"J. Cell. Biol. 111 (6 Pt 2), 2939–2949 (1990).

32. M. Gmachl and G. Kreil, "Bee Venom Hyaluronidase is Homologous to a Membrane Protein of Mammalian Sperm," Proc. Natl. Acad. Sci. USA 90 (8), 3569–3573 (1993).


ADVERTISEMENT

blog comments powered by Disqus
LCGC E-mail Newsletters

Subscribe: Click to learn more about the newsletter
| Weekly
| Monthly
|Monthly
| Weekly

Survey
FDASIA was signed into law two years ago. Where has the most progress been made in implementation?
Reducing drug shortages
Breakthrough designations
Protecting the supply chain
Expedited reviews of drug submissions
More stakeholder involvement
Reducing drug shortages
70%
Breakthrough designations
4%
Protecting the supply chain
17%
Expedited reviews of drug submissions
2%
More stakeholder involvement
7%
View Results
Eric Langerr Outsourcing Outlook Eric LangerRelationship-building at Top of Mind for Clients
Cynthia Challener, PhD Ingredients Insider Cynthia ChallenerRisk Reduction Top Driver for Biopharmaceutical Raw Material Development
Jill Wechsler Regulatory Watch Jill Wechsler Changes and Challenges for Generic Drugs
Faiz Kermaini Industry Insider Faiz KermainiNo Signs of a Slowdown in Mergers
Ebola Outbreak Raises Ethical Issues
Better Comms Means a Fitter Future for Pharma, Part 2: Realizing the Benefits of Unified Communications
Better Comms Means a Fitter Future for Pharma, Part 1: Challenges and Changes
Sandoz Wins Biosimilar Filing Race
NIH Translational Research Partnership Yields Promising Therapy
Source: Pharmaceutical Technology,
Click here